AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

By T. Batchelor, A. Sorensen, E. di Tomaso, Wei-Ting Zhang, D. Duda, K. Cohen, Kevin Kozak, D. Cahill, P. Chen, M. Zhu and 11 more. Cancer Cell, 2007

1,814 citations recorded by the source corpus.

Subfields: Cancer Research, Genetics, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/526e612e06b4e93936440597336fbb3d7b913af5

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

In Genetics

In Molecular Biology

Citations in the corpus

VEGF in Signaling and Disease: Beyond Discovery and Development (2019, background): “A phase I (Batchelor et al., 2007) and a phase II (Batchelor et al.”
Delivering nanomedicine to solid tumors (2010, neutral): “and recurrent glioblastoma patients receiving cediranib”
NORMALIZATION OF THE VASCULATURE FOR TREATMENT OF CANCER AND OTHER DISEASES (2011, neutral): “In contrast, a recent report has documented intratumoral hypoxia in rodents bearing GBM treated with bevacizumab, but this study only examined tumors at later timepoints and did not explore temporal kinetics of such changes (166).”
Angiogenic signaling pathways and anti-angiogenic therapy for cancer (2023, background): “Besides, the up-regulation of bFGF is closely related to poor outcomes of CRC patients after treatment with combined regimens (bevacizumab plus fluorouracil and irinotecan),(164) and GBM patients who are treated with cediranib (AZD2171, a potent VEGFR inhibitor).(165) Angiogenic signaling pathways a”
Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. (2010, background): “enhancement as early as 1 to 2 days after initiation of therapy and commonly result in high radiologic response rates of 25% to 60%.(43-46)”
Angiogenesis in brain tumours (2007, background): “Data consistent with the preclinical findings are beginning to emerge from the clinical settin”
Cancer stem cells in glioblastoma (2015, background): “GBMs express proangiogenic growth factors (Batchelor et al. 2007), withCSCs driving neoangiogenesis with high levels of VEGF (Bao et al. 2006b).”
Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. (2013, positive): “Similar to our mouse model, normalization began by day 1, but the normalization window in patients lasted for at least 1 month—long enough for almost a full course of radiation therapy (Data Supplement Fig S6).(85) All this clinical work showed that anti-VEGF therapies could normalize tumor vessels.”
Exciting New Advances in Neuro-Oncology (2010, background): “73 These alternative proangiogenic pathways may drive angiogenesis in the setting of VEGFR inhibition.”
Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma (2011, background): “flow and oxygenation (normalization hypothesis) (1, 21, 36).”
Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. (2008, result): “This is in accordance with the concept suggesting that antiangiogenic agents may temporarily lead to “normalization” of aberrant tumor vasculature, resulting in more efficient delivery of drugs and oxygen to the tumor.(39,40) In a recent trial, addition of the antiangiogenic integrininhibitor cileng”